Eli Lilly CEO says Foundayo accounts for one-third of new GLP-1 pill patients
Eli Lilly is increasing future manufacturing capacity for Foundayo, its obesity pill, as it seeks to catch up with Novo in the GLP-1 pill market, according to CNBC. Lilly CEO told the outlet that one-third of new patients taking GLP-1 pills are using Foundayo, although the supplied report does not provide a patient total or clarify the measurement period.
Eli Lilly is ramping up future manufacturing for Foundayo, its obesity pill, as the drugmaker tries to catch up with Novo in the GLP-1 pill market, CNBC reported.
Lilly’s CEO told CNBC that one-third of new GLP-1 pill patients are taking Foundayo. The supplied report does not specify the number of patients or the period covered by that figure.
THE QUESTIONS THIS EVENT LEAVES BEHIND
What patient data and time period support the one-third figure?
How much additional production capacity is Eli Lilly planning for Foundayo?
What factors allowed Novo to gain an early lead in the GLP-1 pill market?
How could increased supply affect access to GLP-1 pills?
What conditions would determine whether Lilly closes the gap with Novo?
YOUR QUESTION
Does this story leave you with another question?
Send us the question the report did not answer. It may become the next question IAQ investigates.
GLOBAL CURIOSITY MAP · AUGUST 2026